Publications - University of Maryland School of Medicine

advertisement
CURRICULUM VITAE
Jeffrey C. Fink, M.D., M.S.
Professor, Department of Medicine and Epidemiology (secondary)
University of Maryland School of Medicine
Education
1979 - 1983
B.A.
Clark University, Worcester, Massachusetts
1983 - 1987
M.D. Case Western University School of Medicine, Cleveland, Ohio
1994 - 1996
M.S.
Master of Science Program, Department of Epidemiology
School of Public Health and Community Medicine
University of Washington, Seattle, Washington
Post Graduate Education
1987 - 1990
Intern and Resident in Medicine
University of Washington
Seattle, Washington
1993 - 1994
Clinical Fellow, Division of Nephrology
University of Washington
Seattle, Washington
1994 - 1996
Research Fellow, Division of Nephrology
University of Washington
Seattle, Washington
Certifications
1990-2000
1996-2006
2000-2010
2000-2014
Diplomate, American Board of Internal Medicine
Diplomate, American Board of Internal Medicine, Nephrology
Recertified, Diplomate, American Board of Internal Medicine
Recertified, American Board of Internal Medicine, Nephrology
Medical Licensures
1987
1990
1992
1993
1996
- 1990
- 1992
- 1993
- 1996
- present
Washington (inactive)
Massachusetts (inactive)
California (inactive)
Washington (inactive)
Maryland (active)
Jeffrey C. Fink, M.D., M.S.
Page 2 of 21
Employment History
Academic Appointments
1990 - 1992
Assistant Professor of Medicine
Division of General Internal Medicine, Department of Medicine
Tufts University School of Medicine, Boston, MA
1992 - 1993
Assistant Professor of Medicine
Division of General Internal Medicine, Department of Medicine
University of Southern California, Los Angeles, CA
1996 -2002
Assistant Professor, Departments of Medicine and Epidemiology Division
of Nephrology
University of Maryland School of Medicine (UMSOM), Baltimore, MD
2002 - 2011
Associate Professor, Departments of Medicine and Epidemiology
(secondary)
Division of Nephrology (UMSOM)
July 2011-
Professor, Departments of Medicine and Epidemiology (secondary)
Division of Nephrology (UMSOM)
Other Employment
1990 - 1992
Staff Physician
New England Medical Center, Boston, MA
1992 - 1993
Staff Physician
University of Southern California Medical Center
Los Angeles County Medical Center, Los Angeles, CA
1996 - present
Staff Physician
University of Maryland Medical Center (UMMC)
Baltimore VA Medical Center, (BVMAC), Baltimore, MD
Professional Society Memberships
1990 - present
1993 - present
1993 - present
1999 - 2007
2001 - 2007
American College of Physicians
National Kidney Foundation
American Society of Nephrology
American Society of Transplantation
American Heart Association
Jeffrey C. Fink, M.D., M.S.
Page 3 of 21
Honors and Awards
1982
1999
2005
2011
Phi Beta Kappa, Clark University
American Society of Nephrology, Carl W. Gottschalk Research Award
Fellow, American Society of Nephrology
Fellow, National Kidney Foundation
Clinical Activities
2000 - present
Founder and Director, Early Renal Insufficiency (ERI) Program (2 clinics)
UMMC ERI Clinic (established 2000)
Over 800 patients seen since inception with 250 active patients per year
Pilot site for NIH National Kidney Disease Education Program
educational outreach activities
Platform for multiple clinical research activities
Showcase program for junior faculty recruitment
Duties: 0.5 day clinic; 0.25 day administrative
Baltimore VAMC ERI clinic (established 2001)
Over 1200 patients seen since inception with 530 active patients per year
Extension of Early Renal Insufficiency (ERI) program from UMMS
Platform for multiple clinical research activities
Duties: 0.5 + 0.25 day clinic; 0.25 day administrative
Administrative Services
Institutional Service (University of Maryland)
2000-2002
School of Medicine Dean’s Council
2001
Faculty Practice Office, Space Committee
2005-2007
Faculty Senate
2006-present
UMSOM Institutional Review Board
2006-present
UMSOM GCRC Advisory Committee
2008
Director, Baltimore VA Pre-transplant services
Local and National Service
1992
1997 - 2007
1997 - 2006
2001 - 2004
2001 - 2002
2001 - 2002
2002
2002 - 2010
2002 - present
Expert Witness for United States Attorney, U.S. vs. Smushkevich, et al.
National Kidney Foundation of Maryland, Medical Advisory Board
Mid-Atlantic Renal Coalition, Medical Research Board
National Kidney Foundation of Maryland, Grant Review Committee
American Society of Nephrology, Clinical Science Committee
Editorial Board, American Journal of Kidney Disease
National Kidney Foundation, Career Development Grant Review
Committee
Maryland Kidney Commission, (Chair 2002-2006; 2009 - 2010)
NIDDK Chronic Renal Insufficiency Cohort (CRIC) Steering Committee
Jeffrey C. Fink, M.D., M.S.
Page 4 of 21
2003 - 2004
2004 - 2007
2004 - 2009
2006 - present
2006 - present
2008
2008
2009
2009 - present
2009 - present
2009 - 2010
2009
2009
2009
2009 - present
2010 - present
2010
2010- present
2011- present
2012
2012
2012
National Kidney Disease Education Program, Baltimore Co-Chairman
Editorial Board, Journal of the American Society of Nephrology
American Society of Nephrology, Chronic Kidney Disease Advisory
Committee
Paul Teschan Research Fund Grant Reviewer
NIDDK Data Safety and Monitoring Board (DSMB) for Clinical Trial of
Oral versus IV Iron in CKD Patients (PI Agarwal)
NIH Special Emphasis Scientific Review Group
Ancillary Studies in the Natural History of Acute Kidney Injury
ZDK1 GRB-7 (M1)
NIH Scientific Review Group
Pilot and Feasibility Grants in Kidney Disease (PAR 06-113) ZRG1
RUS-F S (7/24/08)
NIH Scientific Review Group
Nephrology and Urology Clinical and Small Business Grants 2009/05
ZRG1 DKUS-G (51) S (4/6-4/7)
Associate Editor, American Journal of Kidney Disease
Editorial Board, Clinical Nephrology
American Society of Nephrology, Clinical Science Committee
NIH Scientific Review Group, Chair
Pilot and Feasibility Grants in Kidney and Urological Disease
ZRG1 DKUS-G (51) (10/08-10/13)
NIH Scientific Review Group
CKD Biomarkers Ancillary Studies
ZDK1 GRB-6 (J1) 1 (11/16)
NIH Scientific Review Group
NIDDK R01 Ancillary Studies
ZDK1 GRB-G (J4) 1 (11/20/09)
NIDDK CRIC Study Publication Executive Committee (Co-chair)
Associate Editor, Clinical Journal of the American Society of Nephrology
ZDK1 GRB-7 (J3) (12/07/10)
NIH Scientific Review Group
Pediatric Ancillary Study to ASSESS-AKI
American Society of Nephrology, CKD Advisory Group
American Society of Nephrology, Quality and Patient Safety Task Force
and Choose Wisely Initiative (ABIM)
ZRG1 DKUS-L (11) B
NIH Scientific Review Group
Review of Nephrology Small Business Applications
ZRG1 PSE-N (57) R (4/19/12)
NIH Scientific Review Group
FIRCA and GRIP in Behavioral/Social Sciences
ZRG1 DKUS-L 80 S (6/25/12-6/26/12)
NIH Scientific Review Group, Study Section Chair
Clinical Nephrology/Urology Special Emphasis Panel
Jeffrey C. Fink, M.D., M.S.
Page 5 of 21
2012
PAR-DK-090247 Ancillary Studies to Major Ongoing Clinical Research
Studies to Advance Scientific Interest within NIDDK (R01) (7/11/12)
NIH Scientific Review Group, Study Section Chair
Teaching Service
Residents/Fellows
1996 - 1998
Attending on UMMC Medical Service, 1 month per year
Conducted daily teaching rounds and weekly lectures, 2 hours per day
4 medical residents per month
2007 - present
Attending on Medical Service, BVAMC 1 month per year
Conducted daily teaching rounds and weekly lectures
4 medical residents per month
2007 - 2009
Attending on Transplant Service, UMMC 1 month per year
Conduct daily teaching rounds 2 surgical residents in conjunction with
surgery attending, 1 hour per day
1996 – 1998
Renal Journal Club
Lead 3 to 4 one hour conferences per year; attended by 3-4 nephrology
fellows
Students
1996 – 1998
Attending on UMMC Medical Service, 1 month per year
Conducted daily teaching rounds and weekly lectures, 2 hours per day
2 third yr medical students per month
2007 - present
Attending on Medical Service, BVAMC, 1 month per year
Conducted daily teaching rounds and weekly lectures, 2 hours per day
2 third yr medical students, and 1 fourth yr medical student per month
1997 - 2000
Small Group Leader, Renal Pathophysiology and Therapeutics
Lead 3 small group sessions per year, 2 hours per session
Attended by 5-10 second year medical students
1997 - 2000
Small Group Leader, Cardiovascular Pharmacology
Lead 2 small group sessions per year, 2 hours per session
Attended by 5-10 first year medical students
2000
Department of Epidemiology Clinical Epidemiology Seminar
Jeffrey C. Fink, M.D., M.S.
Page 6 of 21
1 hour lecture/25 medical students and fellows (July 17)
2000 - present
Early Renal Insufficiency Teaching Conference, 1 hour per month
Conduct monthly conference attended by 1 nurse practitioner, nephrology
fellows, 2 additional staff physicians and staff (1 RN, 1dietician, 1 SW, 1
administrative person
2001 - 2003
Department of Medicine Continuing Medical Education Program
1 hour/50-75 guest physicians (June 18)
2005
Ambulatory care conference, University of Maryland
1 hour/20 medical residents (July 29)
2006
Small group March 31st Acid Base, 2 hours/20 medical students
2008
Small groups April 1 & 2nd 8-10AM Renal Pathophysiology
2 hours per session/20 medical students per session
2009
Renal Pathophysiology and Therapeutics
Small groups March 25, 26, 27, April 1 & 3
2 hours per session/20 medical students per session
2010
Renal Pathophysiology and Therapeutics
Small group April 8, 2 hours/20 medical students
2012
Renal Pathophysiology and Therapeutics
Small group Nov 30, 2 hours/20 medical student
Research Mentoring
Students
1996
Kennedy Gabregiorgish, 3rd year medical student, 20 hours mentoring
1997
Mark Flasar, 3rd year medical student, 20 hours mentoring
2006
Yonaton Spotler, 3rd year medical student, 20 hours mentoring
(see publication)
2008
Lisa Einhorn, 1st year medical student, 20 hours mentoring
(see publication)
2008
Maureen Moen, 1st year medical student, 20 hours mentoring American
Society of Nephrology Student Research Fellow
(see publication)
Jeffrey C. Fink, M.D., M.S.
Page 7 of 21
2009
Erica Chapin, 1st year medical student, 20 hours mentoring
(see publication)
2010
Krupa Patel, 1st year medical student, 20 hours mentoring
American Society of Nephrology Student Research Fellow
(see publication)
2011
Nizar Dowla, 1st year medical student, 20 hours mentoring
American Society of Nephrology Student Research Fellow
2011
Iris Hartley, 1st year medical student, 20 hours mentoring
Residents
1998
Rachel (Burdick) Fissel, 2nd year resident, 20 hrs mentoring (see
publication)
1999
Manoj Reddy, 2nd year resident, 20 hrs mentoring (see publication)
2000
Daniel Weiner, 3rd year resident, 20 hours mentoring
Fellows
2004 - 2007
Charlotte Jones-Burton, MD, MS Renal Fellow, (see publications)
80 hours mentoring, NRSA Fellow Award Recipient
Faculty
2005 - 2007
Stephen Seliger MD, MS, Assistant Professor (see publications)
80 hours direct mentoring
K-23 award recipient
2007 - 2009
Afshin Parsa, MD, MPH, Assistant Professor
60 hours direct mentoring
K-12 Institutional award recipient
2010 - present
Clarissa Diamantidis, MD, MS, Assistant Professor (see publications)
60 hours direct mentoring (to date)
Mentoring Committee (submitted K-23 or equivalent award)
Grant Support
Active Grants
Jeffrey C. Fink, M.D., M.S.
Page 8 of 21
10/01/01 – 06/30/13 Site Investigator, 20% effort (PI: Appel)
NIDDK UO1, DK61022
Chronic Renal Insufficiency Cohort Study
Annual direct cost (to site): $224,961
Total direct cost (to site): $1,639,923
CRIC is a multi-center cohort study examining the natural history of
persons with chronic kidney disease (n = 3939). Dr Fink is the site PI
overseeing study activities on 256 local enrollees and serving as a member
of the study steering committee.
07/01/10 – 06/30/15 Principal Investigator, 20% effort (Fink)
NIDDK 1R01 DK084017-01A1 (scored at 2nd percentile)
“Does under-recognition of kidney disease affect patient safety?”
Annual Direct Costs: $340,521
Total Direct Costs: $1,872,962
This grant funds the Safe Kidney Care project which will prospectively
evaluate the impact of a Medical ID alert bracelet on chronic kidney
disease recognition and assess to what extent this improves the incidence
of disease-specific safety events. Will also enroll a parallel cohort
tracked for the baseline rate of safety events in the target population.
9/20/11 – 8/31/15
Principal Investigator, 20% effort (Fink)
NIDDK 1R01DK090008-01 (scored at 5th percentile)
Do safety events account for adverse outcomes in CKD?
Annual Direct Costs: $343,731
Total Direct Costs: $1,189,292
This grant is an epidemiological analysis of data from the NIDDK-funded
CRIC study (see NIDDK UO1, DK61022) to identify the frequency of an
array of adverse safety events that are pertinent to kidney disease and to
determine whether these events account for some portion of poor
outcomes in this disease.
Pending grants
7/1/13-6/30/18
Principal Investigator, 20% effort (Fink)
NIDDK 1U01 DK099858 (submitted Nov 2012)
PILOT STUDIES OF CANDIDATE THERAPIES FOR CHRONIC
KIDNEY DISEASE
Evaluating the safety and tolerability of a candidate therapy for CKD
Jeffrey C. Fink, M.D., M.S.
Page 9 of 21
This grant proposes the PI’s center to serve as participating clinical center
in the CKD Pilot Trials Network and outlines a protocol to examine the
safety and tolerability of pirfenidone as a therapy for CKD
11/1/13 – 10/30/15
Principal Investigator, 20% effort (Fink), planned re-submission 3/13
NIDDK 1R21 DKR21DK096204 (initial submission: 37th percentile)
Patient safety monitoring in kidney disease with an eDiary
This grant proposes to evaluate an interactive voice response system to
record patient-experienced safety events among pre-dialysis CKD and
ESRD patients outside the clinic and dialysis unit.
Completed Grants
Extramural grants
07/97– 06/98
Principal Investigator, 2.5% effort
“Protein Catabolic Rate in the United States”
National Kidney Foundation, Maryland Chapter
Total award $4000
Total direct cost $4000
07/98 – 06/99
Principal Investigator, 2.5% effort
“How Variable is Achieved Dialysis Adequacy of ESRD Patients”
National Kidney Foundation, Maryland Chapter
Total award $3250
Total direct cost $3250
07/99 – 06/00
Principal Investigator, 10% effort
“Chronic Allograft Nephrology: A Single Center Study of its Predictors
and Outcomes.”
Hoffman-LaRoche Pharmaceuticals
Total award $41,300
Total direct cost $34,417
07/99 – 06/01
Principal Investigator, 20% effort
“Role of State and Center Effects in Dialysis Adequacy.”
American Society of Nephrology- Carl W. Gottschalk Research Award
Total Award $150,000
Total direct cost $136,364
09/04 – 07/07
Principal Investigator, 20% effort
“Center Effects Influence on Anemia and mortality”
NIH/NIDDK 1 R21 DK064126-01A1
Total award $200,000
Direct cost $148,000
Jeffrey C. Fink, M.D., M.S.
Page 10 of 21
09/03 – 08/07
Director, Kidney Disease Research Core, 10% effort
Project EXPORT- Comprehensive Centers in Health Disparities
NIH/NCMHD 1P60 MD000532-01 (Wilson)
Total award: $400,000, Direct cost $ 400,000
05/05 – 04/10
Site Investigator, 2% effort
Pulse wave velocity in chronic kidney disease
NIDDK R01 DK067390 (Townsend)
Annual direct cost (to site): $9000
Total direct cost (to site): $45,000
07/06 – 06//10
Principal Investigator, 5% effort
Quality of anemia management and its outcome in the VA
Amgen (administered through BREF)
Annual Direct Costs: $100,000
Total Direct Costs: $198,000
08/07 – 07/10
Principal Investigator, 20% effort
Effect of practice guidelines on care of chronic kidney disease in the VHA
NIDDK 1R21DK075675-01A1
Total award $250,000
Direct cost $172,000
03/06 – 02/11
Site Investigator, 2% effort (PI: Hsu)
CRIC-Plus Study of advanced chronic renal insufficiency
NIDDK R01 DK070939
Annual direct cost (to site): $27000
Total direct cost (to site): $125,000
02/07 – 06/11
Principal Investigator, 5% effort
“Changes in myocardial metabolism with anemia management in CKD”
Amgen
Annual Direct Costs: $127,000
Total Direct Costs: $244,500
9/09 – 8/11
Site Investigator, 1% effort (PI: Grunwald)
R-CRIC Retinopathy in chronic renal insufficiency
NIDDK R01 DK074151
Annual direct cost (to site): $43313
Total direct cost (to site): $43313
Jeffrey C. Fink, M.D., M.S.
Page 11 of 21
Extramural contracts
07/01/01 – 06/30/06 Co-principal Investigator, 10% effort
Principal Investigator: Dr Matthew Weir
Registry of Simulect Treated Living Transplant Recipients
Novartis Pharmaceuticals
Total award-$216,000
Total direct cost $180,000
Intramural grants
07/01/98 – 06/30/99 Principal Investigator, 5% effort
“Disparity between Maryland and Virginia in Referral of ESRD Patients
for Dialysis.”
University of Maryland School of Medicine-Pangborn Award
Total award: $15000
Total direct: cost $15000
07/01/99 – 06/30/00 Principal Investigator, 5% effort
“The Relationship Between Creatinine and Mortality in ESRD Patients”
UMB School of Medicine-Pangborn Award
Total award: $15000
Total direct cost: $15000
05/01/03 – 06/30/08 Principal Investigator, 10% effort
Relationship Between Tobacco and Kidney Disease
Maryland Cigarette Restitution Fund
Total award: $235,000
Direct cost: $235,000
09/01/05 – 07/30/09 Research Mentor (to Dr Afshin Parsa), 2.5% effort
NIH/NCRR 5K12 RR023250 (Shuldiner)
Clinical Research Career Development Award
Direct cost (to mentor): $5000 annually
Publications
Peer-reviewed journal articles
1.
2.
3.
Politser PE, Powell SH, Fink JC. New method for reporting the source of abnormal
activities of LDH in serum. Clinical Chemistry 1986; 32:1517-1524.
Fink JC, Schmid CH, Selker HP. A Decision Aid for Referring Patients with Systolic
Murmurs for Echocardiography. J Gen Int Med 1994; 9:479-484.
Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA. Marked Enzymuria
Following Bone Marrow Transplantation: a Correlate of Veno-occlusive Disease Induced
Jeffrey C. Fink, M.D., M.S.
Page 12 of 21
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Hepatorenal Syndrome. J Am Soc Nephrol 1995; 6:1655-1660.
Fink JC, Cooper MA, Zager RA: Hemodialysis induces tubular injury in patients with
acute renal failure. Renal Failure, 1996; 18: 947-949.
Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen
DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the
treatment of chronic allograft nephropathy. Transplantation, 1997; 64:1706-1710.
Roghmann MC, Fink JC, Polish L, Maker T, Brewrink J, Morris JG, Light PD.
Colonization with Vancomycin-resistant enterococci in chronic hemodialysis patients. Am
J Kidney Dis, 1998; 32:254-257.
Fink JC, Leisenring WM, Sherrard DJ, Weiss NS. Risk factors for avascular necrosis
following bone marrow transplantation: a case control study. Bone 1998; 22:67-71.
Fink JC, Schwartz SM, Bennedetti TJ, Stehman-Breen CO. Increased Risk of Adverse
Maternal and Fetal Outcomes Among Women With Renal Disease. Pediatric and Perinatal
Epidemiology. 1998; 12:277-287.
Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB,
Farney AC, Weir MR, Bartlett ST. Mycophenolate Mofetil reduces the risk of acute
rejection less in African-American than in Caucasian kidney recipients. Transplantation
1998; 65:242-248.
Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Cangro CB, Fink JC, Bartlett
ST. Chronic pancreas allograft rejection: morphologic evidence of progression in needle
biopsies and proposal of a grading scheme. Transplantation Proceedings, 1999; 31:614.
Fink JC, Armistead N, Turner M, Gardner J, Light P. Hemodialysis adequacy in Network
5: disparity between states and the role of center effects. Am J Kidney Dis, 1999; 33:97103.
Fink JC, Burdick RA, Kurth S, Armistead N, Turner M, Shickle L, Light PD. The
significance of serum creatinine values in incident end stage renal disease patients. Am J
Kidney Dis 1999; 34: 694-701.
Drachenberg CB, Beskow CO, Cangro CB, Bourquin PM, Simsir A, Fink J, Weir MR,
Klassen DK, et al. Human polyoma virus in renal allograft biopsies: morphological
findings and correlation with urine cytology. Human Pathology 1999; 30, 970-977.
Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB,
Blahut S, Papadimitriou. Islet cell damage associated with tacrolimus and cyclosporine:
morphological features in pancreas allograft biopsies and clinical correlation.
Transplantation 1999; 68:396-402.
Nogueira JM, Cangro CB, Fink JC, Klassen DK, Gardner J, Schweitzer E, Wiland A,
Flowers J, Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A comparison of
recipient renal outcomes with laparoscopic versus open live donor nephrectomy.
Transplantation 1999; 67:722-728.
Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C,
EJ Schweitzer, Bartlett ST. Histologic grading of acute allograft rejection in pancreas
needle biopsy. Transplantation, 1999; 66: 1741-1745.
Passalacqua JA, Wiland AM, Fink JC, Bartlett ST, Evans DA, Keay S. Increased
incidence of postoperative infections associated with peritoneal dialysis in renal transplant
recipients. Transplantation 1999; 68:535-540.
Weir MR and Fink JC. Post-transplant Diabetes Mellitus: risks versus benefits with
current immunosuppressive medications. Am J Kidney Dis; 1999 34:1-14.
Jeffrey C. Fink, M.D., M.S.
Page 13 of 21
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro C, Schweitzer E, Bartlett
ST. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of
mycophenolate mofetil on progression of renal disease. Transplant Proceedings, 1999; 31:
1296-1287.
Fink JC, Gardner JF, Armistead NC, Turner MS, Light PD. Within center correlation in
dialysis adequacy. J Clin Epidemiology 2000; 53: 79-85.
Jacobs SC, Cho E, Dunkin, BJ, Flowers JL, Schweitzer E, Cangro C, Fink J, Farney A,
Philosophe B, Jarrell B, Bartlett ST. Laparoscopic live donor nephrectomy: the University
of Maryland 3-YEAR experience. J Urol 2000; 164:1494-1499.
Stehman-Breen CO, Miller L, Fink J, Schwartz SM. Preeclampsia and premature labor
among women with hematuria. Paediatric and Perinatal Epidemiology 2000; 14:136-140.
Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus
patient-specific factors on variations in dialysis adequacy. J Am Soc Nephrol 2001; 12:
164-169.
Fink JC, Blahut SA, Weir MR, Sawyer R, Henrich WL, Hise MK. The inevitability of
renal function loss in patients with hypercreatinemia. Am J Nephrol 2001; 21:386-389.
Fink JC, Rochussen J, Blahut SA, Reddy M, Light PD. The use of erythropoietin prior to
the initiation of dialysis and its impact on mortality in new end stage renal disease patients.
Am J Kidney Dis 2001; 37: 348-355.
Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ. Bone
density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.
Biol Blood Marrow Transplant 2001; 7: 257-264
Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique
to compare effects of diuretics and angiotensin converting enzyme inhibitors to alleviate
lower extremity edema due to dihydropyridine calcium channel antagonists. Am J
Hypertens 2001; 14: 963-968.
Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The long
term impact of calcineurin inhibitor reduction or discontinuation in patients with declining
kidney function due to chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
Fink JC, Blahut SA, Weir MR. Optimal strategies for modeling the reciprocal of
creatinine versus time in renal transplant recipients and patients with native chronic kidney
disease. Am J Kidney Dis 2002; 39: 753-761.
Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal
transplant recipients: a pilot case-control study. Am J Kidney Disease 2002; 39:10961101.
Fink JC, Zhan M, Blahut SA, Soucie M, McClellan WM. Measuring the efficacy of a
quality improvement program in dialysis adequacy with changes in center effects. J Am
Soc Nephrol 2002; 39 2338-2344.
Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK,
Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR.
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc
Nephrol 2002; 13: 214-2151.
Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS,
Eddington ND Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A in
patients with end-stage renal disease. Clin Pharm Therap 2003; 73: 427-434.
Jeffrey C. Fink, M.D., M.S.
Page 14 of 21
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
Feldman, HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, et al.,
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc
Nephrol; 2003; 14: S148-S153.
Gehr T, Bender F, Fink J, Light P, Elliott K, Shield C, Turner M, Mays C, Parrish J,
Armistead N. Improving adequacy of peritoneal dialysis in ESRD Network 5. Adv Perit
Dial 2003; 19: 86-92.
Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A,
Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST, BK virus nephropathy
diagnosis and treatment: experience at the University of Maryland Renal Transplant
Program. Clin Transpl 2003: 143-153.
Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The
use and interpretation of quasi-experimental designs in infectious diseases. Clin Infect Dis
2004; 38:1586-91.
Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R,
Fink JC. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin
Nephrol 2004; 61: 392-405.
Weir MR, Blahut SA, Drachenberg C, Young C, Papademitriou J, Klassen DK, Cangro
CB, Bartlett ST, Fink JC. Late Calcineurin Inhibitor Withdrawal As A Strategy to Prevent
Graft Loss in Patients with Suboptimal Kidney Transplant Function. Am J Nephrol 2004;
24: 379-386.
Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR Jr, Copenhaver B,
Bartlett ST. Should Living Unrelated Renal Transplants Receive Antibody Induction?
Results of a Clinical Experience Trial. Transplantation 2004; 77: 422-425.
Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L.
Renal function, erythropoietin and anemia of older persons: the InChianti Study. Arch
Intern Med 2005; 165: 2222-2227.
deFilippi C, Fink JC, Nass CM, Loukonen D; Chen C, Christenson R; Pro-B-type
natriuretic peptide predicts coronary disease and left ventricular hypertrophy in
asymptomatic chronic kidney disease patients not requiring renal replacement therapy. Am
J Kidney Dis 2005: 46: 35-44.
Jones-Burton C, Brown J, Miranda M, Passmore SR, Royak Schaler R, Fink JC
“Awareness of the Association Between Smoking and Kidney Disease among AfricanAmericans” JAAMP 2005;16:15-20
Jones –Burton C, Seliger SL, Brown J, Stackiewicz L, Doren Hsu V, Fink JC Racial
variations in erythropoietic response to epoetin alfa in chronic kidney disease and the
impact of smoking. Nephrol Dial Transplant 2005; 20: 2739-2745.
Lu WX, Jones-Burton J, Zhan M, Salzber DJ, Moore Jr J, Fink JC. Survival Benefit of
Recombinant Human Erythropoietin Administration prior to Onset of End-Stage Renal
Disease: Variations across Surrogates for Quality of Care and Time Nephron Clin Pract
2005; 101: c79-c86.
McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC,
Langenberg P, Roghmann MC, Harris AD. The Utility of the Chronic Disease Score and
Charlson Comorbidity Index as Comorbidity Measures for use in Epidemiologic Studies of
Antibiotic-Resistant Organisms. Am J Epidemiol. 2005; 161: 483-493.
Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR. Does dietary salt
increase the risk of progression of kidney disease? Curr Hypertens Rep 2005; 7: 385-391.
Jeffrey C. Fink, M.D., M.S.
Page 15 of 21
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C,
Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR. Effect
of kidney transplantation on left ventricular systolic dysfunction and congestive heart
failure in patients with end-stage renal disease. J Am Coll Card; 2005 45: 1051-1060.
Weir MR and Fink JC. Salt Intake and Progression of Chronic Kidney Disease: An
overlooked modifiable exposure? A Commentary. Am J Kidney Dis 2005; 45: 176-188.
Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR “An Indepth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic
Kidney Disease” Am J Nephrol; 2006 Jun 9;26(3):268-275.
Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type
natriuretic Peptide and B-type natriuretic Peptide for identifying coronary artery disease
and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J
Cardiol 2006; 97: 1530-1534.
McGregor JC, Perencevich EN, Furono JP, Langenberg P, Flannery K, Zhu J, Fink JC,
Bradham DD, Harris AD. Comorbidity risk-adjustment measures were developed and
validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006; 59:1266-73.
Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P,
Seliger SL. Center effects in anemia management of dialysis patients. J Am Soc Nephrol
2007; 18: 646-653.
Jones-Burton C, Seliger SL, Scherer R, Mishra S, Brown J, Weir M, Fink JC. Cigarette
smoking and incident chronic kidney disease: a systematic review. Am J Neprhol 2007;
27: 342-35.
Jones-Burton C, Vessal G, Brown J, Dowling TC, Fink JC. Urinary Cotinine as an
Objective Measure of Cigarette Smoking in Chronic Kidney Disease. Nephrol Dial
Transplant 2007; 22:1950-4.
Spolter YS, Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. The relationship between
dialysis performance measures: adequacy and anemia management. Am J Kidney Dis
2007; 50: 774-781.
Vessal G, Wiland AM, Philosophe B, Fink JC, Weir MR, Klassen DK. Early steroid
withdrawal in solitary pancreas transplantation results in equivalent graft and patient
survival compared with maintenance steroid therapy. Clin Transplant. 2007; 21:491-7.
Seliger SL, Katzel LI, Fink JC, Weir MR, Waldstein SR. Renal function and
cardiovascular response to mental stress. Am J Nephrol. 2008; 28:304-10.
Seliger SL, Zhan M, Hsu VD, Walker L, Fink JC. Chronic Kidney Disease Adversely
Influences Patient Safety. J Am Soc Nephrol. 2008 Dec;19(12):2414-9.
Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY,
Kusek JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR,
Wang H, Feldman HI. A Comparison of Change in Measured and Estimated Glomerular
Filtration Rate in Patients with Nondiabetic Kidney Disease. Clin J Am Soc Nephrol; 2008
Sep; 3(5):1332-8.
Einhorn LM, Zhan M, Hsu VD, Walker L, Moen MF, Seliger SL, Weir MR, Fink JC. The
frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med
2009; 169(12):1156-1162.
Fink JC, Brown J, Hsu VD, Seliger SL, Walker L, Zhan M. CKD as an under-recognized
threat to patient safety. Am J Kidney Disease; 2009 53(4): 681-8.
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D,
Jeffrey C. Fink, M.D., M.S.
Page 16 of 21
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A,
Robinson N, Teal V, and Feldman HI on behalf of the Chronic Renal Insufficiency Cohort
Study Group. The Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline
characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4:
1302-11.
Moen MF, Zhan M, Hsu VD, Walker L, Einhorn LM, Seliger SL, Fink JC. The frequency
and significance of hypoglycemia in chronic kidney disease. Clin J Am Soc Nephrol 4:
1121-1127, 2009.
Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, Guralnik JM, Fried LP.
Advanced Glycation End Products and Their Circulating Receptors and Level of Kidney
Function in Older Community-Dwelling Women. Am J Kidney Dis 2009 53: 51-8.
Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyllysine, an advanced glycation end product, and decline of renal function in older
community-dwelling adults. Eur J Nutr; 2009 Feb;48(1):38-44.
Chapin E, Zhan M, Hsu VD, Seliger SL, Walker LD, Fink JC. Adverse safety events in
chronic kidney disease: the frequency of “multiple hits”. Clin J Am Soc Nephrol; 2010 5:
87-94.
Fink JC, Lodge MA, Smith MF, Hinduja A, Brown J, Dinits-Pensy MY, Dilsizian V. PreClinical Myocardial Metabolic Alterations in Chronic Kidney Disease. Cardiology; 2010
116: 160-167.
Grunwald, JE, Alexander J, Maguire M, Whittock R, Parker C, McWilliams K, Lo JC,
Townsend R, Gadegbeku CA., Lash JP, Fink JC, Rahman M., Feldman H, Kusek J,
Ojo,A,. The CRIC Study Group. Prevalence of Ocular Fundus Pathology in Subjects with
Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. Clin J
Am Soc Nephrol; 2010 5: 867-73.
Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD.
Initiation of anaemia management in patients with chronic kidney disease not on dialysis in
the Veterans Health Administration. Nephrol Dial Transplant; 2010 25: 2237-2244.
Seliger SL, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker LM, Chiou CF, Fink JC.
Timing of Erythropoiesis-stimulating agent (ESA) initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study Clin J Am Soc Nephrol; 2010 5:
882-8.
Semba RD, Fink JC, Sun K, Windham BG, Ferrucci L. Serum Carboxymethyl-Lysine, a
Dominant Advanced Glycation End Product, Is Associated With Chronic Kidney Disease:
The Baltimore Longitudinal Study of Aging. J Ren Nutr; 2010 20: 74-81.
Seliger SL, Zhang A, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis C, Fink JC.
Erythropoiesis-stimulating agents and stroke in chronic kidney disease: a national casecontrol study. Kidney Int 2011 80(3):288-94.
Dalal M, Semba RD, Sun K, Crasto C, Varadhan R, Bandinelli S, Fink JC, Guralnik JM,
Ferrucci L. Endogenous Secretory Receptor for Advanced Glycation End Products and
Chronic Kidney Disease in the Elderly Population. Am J Nephrol 2011 33:313-318.
Kop WJ, Seliger SL, Fink JC, Katz R, Odden MC, Fried LF, Rifkin DE, Sarnak MJ,
Gottdiener JS. Longitudinal Association of Depressive Symptoms with Rapid Kidney
Function Decline and Adverse Clinical Renal Disease Outcomes. Clin J Am Soc Nephrol
2011; 6:834-44.
Jeffrey C. Fink, M.D., M.S.
Page 17 of 21
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
Townsend RR, Anderson AH, Chen J, Gadebegku CA, Feldman HI, Fink JC, et al. for the
CRIC Study Investigators Metabolic Syndrome, Components, and Cardiovascular Disease
Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency
Cohort (CRIC) Study. Am J Nephrol 2011;33:477-48
Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, Chen J, He J, Litbarg
N, Ojo A, Rahman M, Rosen L, Sozio SM, Steigerwalt S, Strauss L, Joffe MM.
Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. Clin J Am Soc
Nephrol, 2011; 2403-10
Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, Ferrucci L, Fried LP. Serum
fibroblast growth factor-23 and risk of incident chronic kidney disease in older communitydwelling women. Clin J Am Soc Nephrol. 2012;7:85-91
Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, McArdle PF.
Genotype-based changes in uric acid affect blood pressure. Kidney Int. 2012 81:502-7
Fink JC, Joy MS, St Peter WL, Wahba IM, Finding a common language for patient safety
in chronic kidney disease Clin J Am Soc Nephrol 2012, 7:689-695.
Diamantidis CJ, Seliger SL, Zhan M, Walker LD, Rattinger GB, Hsu VD, Fink JC. A
varying patient safety profile between blacks and non-blacks with decreased estimated
GFR. Am J Kidney Dis, 2012 60:47-53, PMID: 22483674
Ellingson KD, Palekar RS, Lucero CA, Kurkjian KM, Chai SJ, Schlossberg DS, Vincenti
DM, Fink JC, Davies-Cole JO, Magri JM, Arduino MJ, Patel PR. Vascular access
hemorrhages contribute to deaths among hemodialysis patients. Kidney Int, 2012, ePub.
Patel K, Diamantidis C, Zhan M, Hsu VD, Walker LD, Gardner J, Weir MR, Fink JC.
Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal AntiInflammatory Drug Prescriptions in Chronic Kidney Disease. Am J Nephrol, 2012,
36(1):19-26
Diamantidis CJ, Zuckerman M, Fink W, Hu P, Yang S, Fink JC. Usability of a chronic kidney
disease educational Web site targeted to patients and their family members. Clin J Am Soc Nephrol,
2012, 7(10):1553-60
Grunwald JE, Alexander J, Ying GS, Maguire M, Daniel E, Whittock-Martin R, Parker C,
McWilliams K, Lo JC, Go A, Townsend R, Gadegbeku CA, Lash JP, Fink JC, Rahman M,
Feldman H, Kusek JW, Xie D, Jaar BG; for the CRIC Study Group. Retinopathy and Chronic
Kidney Disease in the Chronic Renal Insufficiency Cohort (CRIC) Study. Arch Ophthalmol. 2012
Sep 1;130(9):1136-1144
Williams AW, Dwyer A, Eddy AA, Fink JC, Jaber BL, Linas S et al, Critical and Honest
Conversations: The Evidence Behind the "Choosing Wisely" Campaign Recommendations by the
American Society of Nephrology. Clin J Am Soc Nephrol, 2012, 82(6):686-92
Weir MR, Townsend RR, Fink JC, Teal V, Sozio SM, Anderson CA, Appel LJ, Turban S,
Chen
J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Steigerwalt S, Strauss L, Joffe MM. Urinary
Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal Insufficiency Cohort
Study. Am J Nephrol 36: 397-404, 2012
Diamantidis CJ, Zuckerman M, Fink W, Aggarwal S, Prakash D, Fink JC. Usability testing and
acceptance of a multi-platform IT Medication Inquiry System (MIS) in chronic kidney disease
(CKD). Am J Kidney Dis (ePub), 2012
Non peer reviewed journal articles
1.
Fink JC, Tucker JC. The artificial heart. Health Matrix 1985.
Jeffrey C. Fink, M.D., M.S.
Page 18 of 21
2.
3.
4.
Fink JC, Henrich WL. How important is volume excess in the etiology of hypertension in
dialysis patients. Semin Dialysis 1999 12: 303-304.
Fink JC, Henrich WL. The outcome of the urban renal patient: The importance of social
factors and center effects. Semin Nephrol 2001; 21: 356-361.
Fink JC. The effect of CKD therapies on serum potassium levels. Nat Rev Nephrol;
2010 6:633-634.
Editorials
1.
2.
3.
Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in
kidney disease. JACC 2008; 51: 146-148.2.Fink JC. Do you need to finish school to get a
kidney transplant? Am J Kidney Disease 2008; 51: 717-718.
Fink JC, Chertow GM. Medication errors: one piece to the patient safety puzzle. Kidney
Int; 2009 76: 1123-1125.
Fink JC. Chronic Kidney Disease as a Potent Risk Modifier for Coronary Heart Disease
in Diabetes Mellitus. JACC Cardiovasc Imaging; 2010; 3: 746-748.
Book Chapters
1.
2.
Fink JC. Current outcomes of dialysis patients. Chapter 43, Principles and Practice of
Dialysis, Third Edition, ed Henrich WL; 2003 pages 662-672.
Fink JC. Current outcomes and quality of care of dialysis patients. Chapter 43, Principles
and Practices of Dialysis, Fourth Edition, ed. Henrich WL; 2009 683-694.
Selected abstract publications
1.
2.
3.
4.
5.
6.
7.
8.
Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patientspecific factors on variations in dialysis adequacy. J Am Soc Nephrol 2000; 11: 230A.
Fink JC, Blahut SA, Light PD, McClellan WM. Assessing the impact of a quality
improvement effort on dialysis adequacy by measuring changes in center effects. J Am
Soc Nephrol 2000; 11: 146A.
Fink JC, Blahut SA, Light PD. The use of erthyropoietin prior to the initiation of dialysis
and its impact on mortality. J Am Soc Nephrol 2000; 11: 146A.
Fink JC, Blahut SA, Weir MR. Geomapping to assess small area variations in
transplantation rates as an initial renal replacement therapy. Transplantation 2000; 69;
S116.
Fink JC, Blahut SA, Weir MR. Small area variations in erythopoietin use prior to initiation
of dialysis in Network 5. J Am Soc Nephrol 2000; 11: 145A.
Fink JC, Wiland AM, Philosophe B, Blahut SA, Rocchusen JR, Wali RK, Weir MR. The
effect of Prograf compared to Neoral on glycemic trends after renal transplantation.
Transplantation 2000; 69, S325.
Fink JC, Wiland AM, Rocchusen JR, Drachenberg CB, Papadimitriou JP. The increased
incidence of BK Polyoma virus in renal transplant recipients treated with Prograf.
Transplantation 2000; 69, S385.
Philosophe B, Fink JC, Wiland AM, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE,
Krishnamurthi V, Bartlett ST. Low kidney rejection rates with basiliximab induction and
Jeffrey C. Fink, M.D., M.S.
Page 19 of 21
9.
10.
11.
12.
13.
14.
delayed introduction of tacrolimus for patients with delayed graft function. Transplantation
2000; 69, S259.
Salmanullah M, Sawyer R, Henrich WL, Weir MR, Fink JC, Hise MK. The natural history
of an elevated creatinine in a VA population. J Am Soc Nephrol 2000; 11: 164A.
Weir MR, Traver M, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The longterm impact of calcineurin inhibitor reduction or discontinuation in patients with declining
kidney function due to chronic allograft nephropathy. Transplantation 2000; 69, S163.
Wiland AM, Fink JC, Philosophe B, Farney A, Schweitzer EJ, Colonna JO, Weir MR,
Bartlett ST. Cost effective measures to administer Thymoglobulin for induction therapy in
pancreas transplant recipients. Transplantation 2000; 69; S408.
Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO. Weir MR,
Bartlett ST. Experience with Thymoglobulin induction therapy in pancreas transplant
recipients. Transplantation 2000; 69; S408.
Fink JC, Blahut SA, Weir MR. Is Renal transplantation adequate treatment for the anemia
of renal disease? J Am Soc Nephol 2001; 12: 887A.
Oniquibo M, Blahut SA, Christenson R, Weir MR, Guitterrez M, Fink JC. Pre-transplant
C-reactive protein as a predictor of chronic allograft nephropathy: a case-control study.
Am J Transplant 2001; 1: 290A.
Major Invited Speeches
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
“Anemia of Chronic Kidney Disease”, University of Virginia Renal Rounds, 8-10
physicians in attendance from renal division. Jan 26, 2001
“Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease”. MCPHahnemann CME Program. 50 physicians in attendance including faculty and housestaff
from the institution. April 25, 2001
“Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease”. Easton
Memorial Hospital Grand Rounds. 12 physicians from the hospital in attendance. May 4,
2001
“Anemia of Chronic Kidney Disease”. Virginia Assoc. of Family Practice Physicians,
Annual Meeting. 100 family practice physicians in attendance. June 18, 2001
“Epidemiology of polyomovirus infection in transplantation”. NIH, NIAID Scientific
Advisory Conference, Bethesda, Maryland. 25 physician attendees. August 13, 2002
“Polyomavirus infection in renal transplantation”. University of Pennsylvania, Transplant
Grand Rounds. 15 Physicians in attendance. January 15, 2003
“Polyomavirus infection in renal transplantation”. Washington Hospital Center, Transplant
Grand Rounds. 20 Physicians in attendance. February 19, 2003
“Managing Chronic Kidney Disease”. Perry Point VA Medical Center, Medical Grand
Rounds. 20 Physicians in attendance. August 27, 2003
“Managing Chronic Kidney Disease”. Washington VA Medical Center, Nephrology
Rounds.15 Physicians in attendance. October 1, 2003
“Analgesic Nephropathy: recommendations for warning labels”. Staff members of US
Senate Government Affairs Committee. Washington DC. 10 Senate staffers present.
November 5, 2003
“Clinical care of Chronic Kidney Disease”. University of Maryland, Department of
Medicine CME program. 100 physicians present. June 9, 2004
Jeffrey C. Fink, M.D., M.S.
Page 20 of 21
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
“Clinical care of Chronic Kidney Disease”. University of Maryland Department of Family
Practice CME program. 100 physicians present. July 2, 2004
“Baltimore Coalition activities”. National Kidney Disease Education Program, NIH
Steering Committee. 30 physicians and attendees present. June 11, 2004
“Benefits of a Chronic Kidney Disease clinic”. American Society of Nephrology, Renal
Week. St Louis, Missouri. 75 physicians in attendance. October 28, 2004
“Chronic Kidney Disease Management in primary care”. Ohio State University Medical
Grand Rounds. 60 physicians in attendance. June 30, 2005
“Management of Chronic Kidney Disease”. Mercy Medical Center, Baltimore. 50
physicians in attendance. January 11, 2006
“Center effects in hemodialysis”. Mid-Atlantic Nephrology Young Investigators Forum.
Baltimore, MD. 25 physicians in attendance. March 15, 2006
“Chronic kidney disease management: Same old swan song?” National Capital
Nephrology Forum. National Naval Medical Center, Bethesda MD. 25 physicans in
attendance. April 12, 2006
“Promoting the Partnership”. Symposium on Transplant and Dialysis Center
Relationships. Maryland Commission on Kidney Disease. UMBC Technology Center. 75
Health Care Providers in Attendance. October 3, 2006
“Chronic Kidney Disease”. University of Maryland Mini-Medical School College of
Southern Maryland. 15 participants. October 21, 2006
“Chronic kidney disease management: Same old swan song?” Grand rounds, Uniformed
Services University of Health Sciences, Andrews Air Force Base. 50 participants. October
27, 2006
“Chronic kidney disease management: Same old swan song?” Renal Grand Rounds, JHUBayview Medical Center. 20 participants. December 6, 2006
“Kidney Disease”. University of Maryland Statewide Health Network. Heritage United
Church of Christ, Baltimore, MD. 35 attendees. June 2, 2007
“Irreversible Renal Failure: Challenges and Considerations with Dialysis and
Transplantation” Learning Institute for Management of Chronic Kidney Disease, Boston,
Massachusetts. 40 attendees. October 24, 2007
“View from a CRIC (Chronic Renal Insufficiency Cohort Study) Clinical Center”. Chronic
Kidney Disease-Japanese CRIC meeting at the American Society of Nephrology
conference, San Francisco, California. 40 attendees present. November 3, 2007
“The Relationship between Smoking and Chronic Kidney Disease (CKD): Developing
Evidence Using Biological and Epidemiological Methods”. University of Maryland
Statewide Health Network, Baltimore, MD. 100 physicians and attendees present.
November 19, 2007
“Update on Chronic Kidney Disease”. University of Maryland Family Practice Grand
Rounds
35 participants. December 5, 2007
“Chronic Kidney Disease and Patient Safety”. Renal Disease Interest Group. Welch
Center, Johns Hopkins University. 20 participants. January 23, 2008
“Natuiretic peptides in ESRD. American Society of Nephrology Annual Meeting,
Philadelphia, PA. 300 participants. November 6, 2008
“Disease specific safety indicators in CKD”. Renal Disease Interest Group. Welch Center,
Johns Hopkins University. 20 participants. May 27, 2009
Jeffrey C. Fink, M.D., M.S.
Page 21 of 21
32.
33.
34.
35.
36.
37.
38.
“Walk the Line”. Challenge of Hypoglycemia in the CKD patient with Diabetes. National
Kidney Foundation. Case-based CME webcast. March 1, 2010“Chronic kidney disease as
a crucible of patient safety”. Welch Center Rounds, Johns Hopkins University. 40
participants. December 8, 2010
“Chronic kidney disease as a crucible of patient safety”. George Washington University,
Department of Medicine, Grand rounds. 150 participants. August 25, 2011
“Chronic kidney disease as a crucible of patient safety” Cleveland Clinic Glickman
Urologic and Kidney Institute, Renal Grand Rounds, 50 participants, February 27, 2012
“Subcinical harm from medication errors in chronic kidney disease”, Division of Applied
Pharmacology Research, Food and Drug Administration, 20 participants, March 23, 2012
(host: Rodney Rouse PhD)
“Cohort studies”, University of Maryland Department of Medicine Residents, May 11,
2012, 6 participants
Transitioning to Independence: A Professional Development Symposium for UMB Career
Development Awardees; Creating a Thriving Research Program: Lessons Learned from
Successful UMB Investigators: Panel participant, 25 participants, June 1, 2012 (host:
Wendy Sanders, Asst Dean, Career Development, University of Maryland, Batimore).
An Opportunity to Avoid Medication Errors in Patients with CKD? Kidney Week
(American Society of Nephrology National meeting), San Diego, CA, November 4, 2012,
(moderator: Andrew Narva, MD). 50 participants
Download